Trial Profile
A Single-dose, Open-label, Randomised, Crossover Bioequivalence Study in Healthy Young Men Comparing Two Formulations of Escitalopram.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Depressive disorders; Generalised anxiety disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia
- Focus Pharmacokinetics
- 09 Nov 2011 Results reported at the 11th International Forum on Mood and Anxiety Disorders.
- 18 Jul 2011 New trial record